Skip to NavigationSkip to content
OSI Pharmaceuticals
OSI resists Astellas and invites other offers
US company is holding out for a better offer
Lilly acquires rights to testosterone treatment
Signs deal with Acrux for under-arm medication
Conventional hypertension prescribing 'should be reconsidered'
Study suggesting new risk factor could influence NICE guidance
Revolade gets European go ahead
GSK’s orphan drug approved to treat reduced platelet count in patients with a rare blood disorder
>> More News Stories
CME Spotlight: The numbers game

Eugene Pozniak examines the changing face of Continuing Medical Education

>> More Features
>> More News Stories
a site by SiftGroups